Pharmacokinetics and molecular detoxication

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 1, 1996, Pages 23-40

  Cashman, John R ^a   Perotti, Beatrice Y T ^b   Berkman, Clifford E ^a   Lin, Jing ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

(S) nicotine; Carboxylesterases; Cytochrome p450; Environmental chemicals; Flavin containing monooxygenase; Glucuronidation; In vitro in vivo correlations; Interspecies allometric scaling; Organophosphates; Physiological modeling; Toxicokinetics

Indexed keywords

CARBOXYLESTERASE; CYTOCHROME P450; ENVIRONMENTAL CHEMICAL; ENZYME; GLUCURONOSYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE;

BIOCHEMISTRY; DETOXIFICATION; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; MEASUREMENT; METABOLISM; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TOXICOKINETICS;

MAMMALIA;

EID: 0029886440     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s123     Document Type: Review

References (143)

1. Brodie BR, Reid WD, Cho AK, Sipes G, Gillette JR. Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci USA 68:160-164 (1971).
2. Welling PG, Tse FLS. Pharmacokinetics: Regulatory, Industrial, Academic Perspectives. 2d ed. New York:Marcel Dekker, 1991.
3. Benet LZ, Perotti BYT. Drug absorption, distribution, and elimination. In: Burger's Medicinal Chemistry and Drug Discovery, Vol I (Wolff ME, ed). New York:John Wiley & Sons, 1995;113-128.
4. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia:Lea & Febiger, 1989.
5. Benet LZ, Galeazzi RL. Noncompartmental detemination of steady-state volume of distribution. J Pharm Sci 68:1071-1074 (1979).
6. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653 (1977).
7. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040 (1986).
8. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775 (1983).
9. Sacher GA. Relationship of lifespan to brain weight and body weight in mammals. Ciba Found Colloq Aging 5:115-133 (1959).
10. Boxenbaum H, Fertig JB. Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur J Drug Metab Pharmacokinet 9:177-183 (1984).
11. Gascon AR, Calvo B, Hernandez RM, Dominguez-Gil A, Pedraz J. Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions. Pharm Res 11:945-950 (1994).
12. Kim SR, Chow HH, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of cocaine in several mammalian species. Pharm Res 11:S-421 (1994).
13. Owens SM, Hardwick W, Blackall D, McMillan DE. Interspecies scaling of phenylcyclidine (PCP) pharmacokinetic parameters. In: 71st Annual Meeting of the Federation of American Societies for Experimental Biology, 29 March 1987, Washington, DC. Fed Proc 46:867 (1987).
14. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227 (1982).
15. Mordenti J. Chappell W. The use of interspecies scaling in toxicokinetics In: Toxicokinetics and New Drug Development (Yacobi A, Kelly JP, Batra VK, eds). Elmsford, UK:Pergamon Press, 1989;42-96.
16. Boxenbaum H, D'Souza R. Physiological models, allometry, neoteny, space-time and pharmacokinetics. In: Pharmacokinetics: Mathematical and Statistical Approaches (Pecile A, Rescigno A, eds). New York:Plenum Press, 1988;191-214.
17. Dedrick RL, Bischoff KB, Zaharko DZ. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother. Rep Part 1 54:95-101 (1970).
18. Gatti G, Kahn JO, Lifson J, Williams R, Turin L, Volberding PA, Gambertoglio JG. Pharmacokinetics of GLQ223 in rats, monkeys, and patients with AIDS or AIDS-related complex. Antimicrob Agents Chemother. 35:2531-2537 (1991).
19. Ibrahim SS, Boudinot FD. Pharmacokinetics of 2′,3′-dideoxycytidine in rats: application to interspecies scale-up. J Pharm Pharmacol 41:829-834 (1989).
20. Lave T, Schmitt-Hoffman AH, Coassolo P, Valles B, Ubeaud G, Ba B, Brandt R, Chou RC. A new extrapolation method from animals to man: application to a metabolized compound, mafarotene. Life Sci 56:473-478 (1995).
21. Baggot JD. Application of interspecies scaling to the bispyridinium oxime HI-6. Am J Vet Res 55:689-691 (1994).
22. Gombar CT, Harrington GW, Pylypiw HM Jr, Anderson LM, Palmer AE, Rice JM, Magee PN, Burak ES. Interspecies scaling of the pharmacokinetics of N-nitrosodimethylamine. Cancer Res 50:4366-4370 (1990).
23. Jezequel SG. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 46:196-199 (1994).
24. Mordenti J, Chen SA, Moor JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359 (1991).
25. Kaul S, Barbhaiya R. Interspecies scaling of stavudine pharmacokinetics. Pharm Res 11:5-348 (1994).
26. Campbell DB. Can allometric interspecies scaling be used to predict human kinetics? Drug Inf J 28:235-245 (1994).
27. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 19:21-50 (1991).
28. Andersen ME, Clewell HJ, Gargas ML, Smith FA, Reitz RH. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205 (1987).
29. Gabrielsson JL, Johansson P, Bondesson U, Paalzow LK. Analysis of methadone disposition in the pregnant rat by means of a physiological flow model. J Pharmacokinet Biopharm 13:355-372 (1985).
30. Davila DG, Williams DE. The etiology of lung cancer. Mayo Clin Proc 68:170-182 (1993).
31. Smoking-attributable mortality and years of potential life lost: United States, 1988. Morb Mort Wkly Rep 40:62-71 (1991).
32. U.S. Environmental Protection Agency. Smoking and tobacco control. In: Monograph on the Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders, NIH Publ 93-3605. Bethesda, MD:National Cancer Institute, 1993;21-31.
33. Park SB, Jacob P III, Benowitz NL, Cashman JR. Stereosclective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem Res Toxicol 6:880-888 (1993).
34. Berkman CE, Park SB, Wrighton SA, Cashman JR. In vitro - in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 50:565-570 (1995).
35. Benowitz NL, Jacob P III. Nicotine metabolism, pharmacokinetics and pharmacodynamics in man. In: Tobacco Smoking and (S)-Nicotine: A Neurobiological Approach (Martin WR, Van Loon GR, Iwamoto ET, Davis L, eds). New York:Plenum Press, 1987;357-373.
36. Cashman JR, Park SB, Yang Z-C, Wrighton SA, Jacob P III, Benowitz NL. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 5:639-646 (1992).
37. Sepkovic DW, Haley NK, Axelrad CM, Shigematsu A, LaVoie EJ. Short-term studies on the in vivo metabolism of N-oxides of nicotine in rats. J Toxicol Environ Health 18:205-214 (1986).
38. Cashman JR. Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181 (1995).
39. Ziegler DM, Ansher SS, Nagata T, Kadlubar FF, Jakoby WB. N-Methylation: potential mechanism for metabolic activation of carcinogenic primary arylamines. Proc Natl Acad Sci USA 85:2514-2517 (1988).
40. Mirand CL, Chung W, Reed RE, Zhao X, Henderson MC, Wang J-L, Williams DE, Buhler DR. Flavin-containing monooxygenase: a major detoxifying enzyme for the pyrrolizidine alkaloid senecionine in guinea pig tissues. Biochem Biophys Res Commun 178:546-552 (1991).
41. Chambers JP, Hartgraves SL, Murphy MR, Wayner MJ, Kuman N, Valdes JJ. Effects of three reputed carboxylesterase inhibitors upon rat serum esterase activity. Neurosci Biobehav Rev 15:85-88 (1991).
42. Imamura T, Schiller NL, Fukuto TR. Malathion and phenthoate carboxylesterase activities in pulmonary alveolar macrophages as indicators of lung injury. Toxicol Appl Pharmacol 70:140-147 (1983).
43. Makhaeva GF, Veselova VL, Mastriukova TA, Shipov AE, Zhdanova GV. Interaction of various dithio- and thiophosphates containing amino acid fragments with carboxylesterase from rat liver. Bioorg Khim 9:920-925 (1983).
44. Kawabata S, Hayasaka M, Hayashi H, Sakata M, Hatakeyama Y, Orgura N. Phenthoate metabolites in human poisoning. J Toxicol Clin Toxicol 32:49-60 (1994).
45. Heyman E, Hoppe W, Krusselmann A, Tschoetschel C. Organophosphate sensitive and insensitive carboxylesterases in human skin. Chem Biol Interact 87:217-226 (1993).
46. Makhaeva CF, Iankovskaia VL, Odoeva GA, Shestakova NN, Khovanskikh AE. The role of esterases in the toxicity of organothiophosphorus insectoacaracides containing a fragment of mercaptoacetic acid. Bioorg Khim 11:957-962 (1985).
47. Sultatos LG, Shao M, Murphy SD. The role of hepatic biotransformation in mediating the acute toxicity of the phosphorothionate insecticide chlorpyrifos. Toxicol Appl Pharmacol 73:60-68 (1984).
48. Ehrich M, Cohen SD. DDVP (dichlorvos) detoxification by binding and interactions with DDT, dieldrin, and malaoxon. J Toxicol Environ Health 3:491-500 (1977).
49. Chambers JE, Tangeng JJ, Boone S, Chambers HW. Role of detoxication pathways in acute toxicity levels of phosphorothionate inscecticides in the rat. Life Sci 54:1357-1364 (1994).
50. Chambers H, Brown B, Chambers JE. Non-catalytic detoxication of six organophosphorus by rat liver homogenates. Pest Biochem Physiol 36:308-315 (1990).
51. Chambers JE, Chambers HW. Time course of inhibition of acetylcholinesterase and aliesterase following parathion and paraoxon exposure in rats. Toxicol Appl Pharmacol 103:420-429 (1990).
52. Saboori AM, Lang DM, Newcombe DS. Structural requirements for the inhibition of human monocyte carboxylesterase by organophosphorus compounds. Chem Biol Interact 80:327-338 (1991).
53. Wahlländer A, Szinicz L. Detoxification of soman in the perfused rat liver: quantitative uptake and stereoisomer metabolism. Arch Toxicol 64:586-589 (1990).
54. Maxwell DM, Brecht KM, O'Neill BL. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 39:35-42 (1987).
55. Gupta RC, Patterson GT, Dettbarn WD. Acute tabun toxicity; biochemical and histochemical consequences in brain and skeletal muscles of rat. Toxicology 46:329-341 (1987).
56. Clark NW, Scott RC, Blain PG, Williams FM. Fate of fluazifop butyl in rat and human skin in vitro. Arch Toxicol, 67:44-48 (1993).
57. McCracken NW, Blain PG, Williams FM. Human xenobiotic metabolizing esterases in liver and blood. Biochem Pharmacol 46:1125-1129 (1993).
58. Gupta RC, Kadel WL. Concerted role of carboxylesterase in the potentiation of carbofuran toxicity by iso-OMPA pretreatment. J Toxicol Environ Health 26:447-457 (1989).
59. Cantalamessa F. Acute toxicity of two pyrethroids, permethrin and cypermethrin in neonatal and adult rats. Arch Toxicol 67:510-3 (1993).
60. Casida JE, Ueda K, Gaughan LC, Jao LT, Soderlund DM. Structure-biodegradability relationships in pyrethroid insecticides. Arch Environ Contam Toxicol 3:491-500 (1975).
61. Stott WT, Mckenna MJ. Hydrolysis of several glycol ether acetates and acrylate esters by nasal mucosal carboxylesterase in vitro. Fundam Appl Toxicol 5:399-404 (1985).
62. Johnsen H, Odden E, Lie O, Johnsen BA, Fonnum F. Metabolism of T-2 toxin by rat liver carboxylesterase. Biochem Pharmacol 35:1469-1473 (1986).
63. Fonnum F, Sterri SH, Aas P, Johnsen H. Carboxylesterases, importance for detoxification of organophosphorus anti-cholinesterases and trichothecenes. Fundam Appl Toxicol 5:S29-38 (1985).
64. Wei RD, Chu FS. Modification of in vitro metabolism of T-2 toxin by esterase inhibitors. Appl Environ Microbiol 50:115-119 (1985).
65. Durrer A, Walther B, Racciatti A, Boss G, Testa B. Structure-metabolism relationships in the hydrolysis of nicotinate esters by rat liver and brain subcellular fractions. Pharm Res 8:832-839 (1991).
66. Aukerman SL, Brundrett RB, Hartman PE. Detoxification of nitrosamides and nitrosocarbamates in blood plasma and tissue homogenates. Environ Mutagen 6:835-849 (1984).
67. Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 10:392-403 (1985).
68. Inoue M, Morikawa M, Tsuboi M, Ito Y, Sugiura M. Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolyzing activity for ester-type drugs. Jpn J Pharmacol 30:529-535 (1980).
69. Brzenzinski MR, Abraham TL, Stone CL, Dean RA, Bosron WF. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem Pharmacol 48:1747-1755 (1994).
70. Luttrell WE, Castle MC. Species differences in the hydrolysis of meperidine and its inhibition by organophosphate compounds. Fundam Appl Toxicol 11:323-332 (1988).
71. Dickinson RG, Baker PV, Franklin ME, Hooper WD. Facile hydrolysis of meveverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. J Pharm Sci 80:952-957 (1991).
72. Liu K, Guengerich FP, Yang SK. Enantioselective hydrolysis of lorazepam 3-acetate by esterases in human and rat liver microsomes and rat brain S9 fraction. Drug Metab Dispos 19:609-613 (1991).
73. Bosron WF, Dean RA, Brzezinski MR, Pindel EV. Human liver cocaine carboxylesterases. Biochem Pharmacol (in press).
74. Welch S, Lee J. The population distribution of genetic variants of human esterase D. Humangentik 24:329-331 (1974).
75. Coates PM, Mestriner MA, Hopkinson DA. A preliminary genetic interpretation of the esterase isozymes of human tissue. Ann Hum Genet 39:1-20 (1975).
76. Varki A, Muchmore E, Diaz S. A sialic acid-specific O-acetylesterase in human erythrocytes: possible identity with esterase D, the genetic marker of retinoblastomas and Wilson disease. Proc Natl Acad Sci USA 83:882-886 (1986).
77. Lee W, Wheatley W, Benedict WF, Huang C, Lee EY-HP. Purification, biochemical characterization, and biological function of human esterase D. Proc Natl Acad Sci USA 83:6790-6794 (1986).
78. Squire J, Dryja TP, Dunn J, Goddard A, Hofmann T, Musarella M, Willard HF, Becker AJ, Gallie BL, Phillips RA. Cloning of the esterase D gene: a polymorphic gene probe closely linked to the retinoblastoma locus on chromosome 13. Proc Natl Acad Sci USA 83:6573-6577 (1986).
79. Okada Y, Wakabayashi K. Purification and characterization of esterases D-1 and D-2 from human erythrocytes. Arch Biochem Biophys 263:130-136 (1988).
80. Lee EY-HP, Lee W. Molecular cloning of the human esterase D gene, a genetic marker of retinoblasoma. Proc Natl Acad Sci USA 83:6337-6341 (1986).
81. Sparkes RS, Sparkes ME, Wilson MG, Towner JW, Benedict W, Murphree AL, Yunis JJ. Regional assignment of genes for human estetase D and retinoblastoma to chromosome band 13q14. Science 208:1042-1044 (1980).
82. Ward P, Packman S, Loughman W, Sparkes M, Sparkes R, McMahon A, Gregory T, Ablin A. Location of the retinoblastoma susceptibility gene(s) and the human esterase D locus. J Med Genet 21:92-95 (1984).
83. Yunis JJ, Ramsey N. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132:161-163 (1978).
84. Duncan AMV, Morgan C, Gallie BL, Phillips RA, Squire J. Re-evaluation of the sublocalization of esterase D and its relation to the retinoblastoma locus by in situ hybridization. Cytogenet. Cell Genet 44:153-157 (1987).
85. Young LS, Lee EY-HP, To H, Bookstein R, Shew J, Donoso LA, Sery T, Giblin M, Sheilds JA, Lee W. Human esterase D gene: complete cDNA sequence, genomic stucture, and application in the genetic diagnosis of human retinoblastoma. Hum Genet 79:137-141 (1988).
86. Long RM, Calabrese MR, Martin BM, Pohl LR. Cloning and sequencing of a human liver carboxylesterase isoenzyme. Life Sci 48:PL43-49 (1991).
87. Riddle PW, Richards LJ, Bowles MR, Pond SM. Cloning and analysis of a cDNA encoding a human liver carboxylesterase. Gene 108:289-292 (1991).
88. Shibata F, Takagi Y, Kitajima M, Kuroda T, Omura T. Molecular cloning and characterization of a human carboxylesterase gene. Genomics 17:76-82 (1993).
89. Munger JS, Shi G, Mark EA, Chin DT, Gerard C, Chapman HA. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem 266:18832-18838 (1991).
90. Lewis JL, Nikula KJ, Novak R, Dahl AR. Comparative localization of carboxylesterase in F344 rat, beagle dog, and human nasal tissue. Anat Rec 239:55-64 (1994).
91. Mattes PM, Mattes WB. Alpha-naphthyl butyrate carboxylesterase activity in human and rat nasal tissue. Toxicol Appl Pharmacol 114:71-76 (1992).
92. Bogdanffy MS, Kee CR, Hinchman CA, Trela BA. Metabolism of dibasic esters by rat nasal mucosal carboxylesterase. Drug Metab Dipos 19:124-129 (1991).
93. Kuykendall JR, Taylor ML, Bogdanffy MS. Cytotoxicity and DNA-protein crosslink formation in rat nasal tissues exposed to vinyl acetate are carboxylesterase-mediated. Toxicol Appl Pharmacol 123:283-292 (1993).
94. Gan KN, Smolen A, Eckerson HW, La-Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19:100-106 (1991).
95. Smolen A, Eckerson HW, Gan KN, Hailat N, La-Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 19:107-112 (1991).
96. Reiner E, Pavkovíc E, Radíc Z, Simeon V. Differentiation of esterases reacting with organophosphorus compounds. Chem Biol Interact 87:77-83 (1993).
97. Vitarius JA, Sultatos LG. The role of calcium in the hydrolysis of the organophosphate paraoxon by human serum A-esterase. Life Sci 56:125-134 (1995).
98. Fernando G, Gonzalvo MC, Hernandez AF, Villanueva E, Pla A. Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver. Biochem Pharmacol 48:1559-1568 (1994).
99. Sorrenson RC, Primo-Parmo SL, Kuo C-L, Adkins S, Lockridge O, La-Du B. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad USA 92:7187-7191 (1995).
100. Clarke DJ, George SG, Burchell B. Glucuronidation in fish. Aquat Toxicol 20:35-56 (1991).
101. Dutton GJ. Glucuronidation of Drugs and Other Compounds. Boca Raton, FL:CRC Press, 1980.
102. Wall KL, Gao W, Koppele JM, Kwei GY, Kauffman FC, Thurman RG. The liver plays a central role in the mechanism of chemical carcinogenesis due to polycyclic aromatic hydrocarbons. Carcinogenesis 12:783-786 (1991).
103. Sammett D, Lee EW, Kocsis JJ, Snyder R. Partial hepatectomy reduces both metabolism and toxicity of benzene. J Toxicol Environ Health 5:785-792 (1979).
104. Reitz RH, Fox TR, Quast JF, Hermann EA, Watanabe PG. Molecular mechanism involved in the toxicity of orthophenylphenol and its sodium salt. Chem Biol Interact 43:99-119 (1983).
105. Cardona RA, King CM. Activation of the O-glucuronide of the carcinogen N-hydroxy-N-fluroenyl-acetamide by enzymatic deacetylation in vitro: formation of fluorenylamine-tRNA adducts. Biochem Pharmacol 25:1051-1056 (1975).
106. Irving CC. Influence of the aryl group on the reaction of glucuronides of N-arylacethydroxamic acids with polynucleotides. Cancer Res 37:524-528 (1977).
107. Clarke DJ, Burchell B. The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In: Handbook of Experimental Pharmacology: Conjugation and Deconjugation Reactions in Drug Metabolism and Toxicity, Vol 112 (Kauffman FC, ed). New York:Springer-Verlag, 1994;3-44.
108. Miller EC, Miller JA. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 7:2327-2345 (1981).
109. Lorentzen RJ, Tso PO. Benzo(a)pyrenedione/benzo(a)pyrenediol oxidation-reduction couples and the generation of reactive reduced molecular oxygen. Biochemistry 16:1467-1473 (1977).
110. Miller A, Miller EC. Electrophilic sulfuric acid ester metabolites as ultimate carcinogens. Adv Exp Med Biol 197:583-595 (1986).
111. Bock KW. UDP-glucuronosyltransferases and their role in metabolism and disposition of carcinogens. Adv Pharmacol 27:367-383 (1994).
112. Patrianakos C, Hoffmann D. Chemical studies on tabacco. smoke, LXIV. On the analysis of aromatic amines in cigarette smoke. J Anal Toxicol 3:150-154 (1979).
113. Mommsen S, Aagaard J. Tobacco as a risk factor in bladder cancer. Carcinogenesis 4:335-338 (1983).
114. Wilson RH, DeEds F, Cox AJ Jr. The toxicity and carcinogenic activity of 2-acetaminofluorene. Cancer Res 1:595-608 (1941).
115. Kadlubar FF, Miller JA, Miller EC. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37:805-814 (1977).
116. Poupko JM, Hearn WL, Radomski JL. N-Glucuronidation of N-hydroxy aromatic amines: a mechanism for their transport and bladder-specific carcinogenicity. Toxicol Appl Pharmacol 50:479-484 (1979).
117. 1 mice. Food Chem Toxicol 31:343-350 (1993).
118. Mulder GJ, Coughtrie MWH, Burchell B, eds. Conjugation Reactions in Drug Metabolism: An Integrated Approach. Philadelphia:Tayler & Francis, 1990.
119. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 85:8381-8385 (1988).
120. Visser TJ, Kaptein E, van Raaij. Glucuronidation of thyroid hormone with preference for 3,3′,5′-triiodothyronine (reverse T3). FEBS Letters 315:65-68 (1993).
121. Jackson MR, McCarthy LR, Harding D, Wilson S, Coughtrie MWH, Burchell B. Cloning of a human liver microsomal UDP-glucuronosyltransferase cDNA. Biochem J 242:581-588 (1987).
122. Iyanagi T, Haniv M, Sagawa K, Fuju-Kuriyama Y, Watanabe S, Shively JE, Anan KF. Cloning and characterization of cDNA encoding 3-methylcholanthrene-inducible rat mRNA for UDP-glucuronosyltransferase. J Biol Chem 261:15607-15614 (1986).
123. Ralston EJ, English JJ, Dooner HK. Sequence of three bronze alleles of maize and correlation with the genetic fine structure. Genetics 119:185-197 (1988).
124. Hundle BS, O'Brien DA, Alberti M, Beyer P, Hearst JE. Functional expression of zeaxanthin glucosyltransferase from Erwinia herbicola and a proposed urindine diphosphate binding site. Proc Natl Acad Sci USA 89:9321-9325 (1992).
125. Crigler JF, Najjar VA. Congenital familial non-haemolytic jaundice with kernicterus. Pediatrics 10:169-180 (1952).
126. Roy Chowdhury J, Wolkoff AW, Arias IM. Hereditary jaundice and disorders of bilirubin metabolism. In: The Metabolic Basis of Inherited Disease (Scriver CR, ed). 6th ed. New York:McGraw-Hill, 1989;1085-1094.
127. Branchereau S, Ferry N, Myara A, Saato H, Kowai O, Trivin F, Houssin D, Danos O, Heard J. Correction of bilirubin glucuronyltransferase in Gunn rats by gene transfer in the liver using retroviral vectors. Chirurgie 119:642-648 (1993).
128. Gilbert A, Lereboullet P. La cholamine simple familiale. Sem Med 21:241-245 (1901).
129. Cornelius CE. Fasting hyperbilirubinemia in Bolivian squirrel monkeys with a Gilbert's-like syndrome. Adv Vet Sci Comp Med 37:127-147 (1993).
130. Fogelfeld L, Sarova-Pinchas I, Meytes D, Barash V, Brok-Simoni F, Feigl D. Phosphofructokinase deficiency (Tarui disease) associated with hepatic glucuronyltransferase deficiency (Gilbert's syndrome): a case and family study. Israel J Med Sci 26:328-333 (1990).
131. Pang KS, Mulder GJ. A commentary: effect of flow on formation of metabolites. Drug Metab Dispos 18:270-275 (1990).
132. Krijgsheld KR, Koster HJ, Scholtens E, Mulder GJ. Cholestatic effect of harmol glucuronide in the rat. Prevention of harmol-induced cholestasis by increased formation of harmol sulfate. J Pharmacol Exp Ther 221:731-734 (1982).
133. Pandey A, Hassen AM, Benedict DR, Fitzpatrick DW. Effect of UDP-glucuronyltransferase induction on zearalenone metabolism. Toxicol Let 51:302-211 (1990).
134. Viani A, Temellini A, TUsini G, Pacifici GM. Human brain sulphotransferase and glucuronyltransferase. Hum Exp Toxicol 9:65-69 (1990).
135. Rao NJ, Jagadeesan V. Effect of long term iron deficiency on the activities of hepatic and extra-hepatic drug metabolising enzymes in Fischer rats. Comp Biochem Physiol Biochem Mol Biol 110:167-173 (1995).
136. Goud VK, Polasa K, Krishnaswamy K. Effect of turmeric on xenobiotic metabolising enzymes. Plant Foods Hum Nutr 44:87-92 (1993).
137. Iwasaki M, Iwama M, Miyata N, Iitoi Y, Kanke Y. Effects of vitamin E deficiency on hepatic microsomal cycochrome P450 and phase II enzymes in male and female rats. Int J Vitam Nutr Res 64:109-112 (1994).
138. Oka S, Terayama K, Kawashima C, Kawasaki T. A novel glucuronyltransferase in nervous system presumably associated with the biosynthesis of HNK-1 carbohydrate epitope on glycoproteins. J Biol Chem 267:22711-22714 (1992).
139. Dulik DM, Fenselau C. Species-dependent glucuronidation of drugs by immobilized rabbit, rhesus monkey, and human UDP-glucuronyltransferases. Drug Metab Dispos 15:473-477 (1987).
140. Cretton EM, Sommadossi JP. Modulation of 3′-azido-3′-deoxythy-midine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem Pharmacol 42:1475-1480 (1991).
141. Chaudhuri NK, Servando OA, Manniello MJ, Luders RC, Chao DK, Bartlett MF. Metabolism of tripelennamine in man. Drug Metab Dispos 4:372-387 (1976).
142. Fishcher LJ, Thies RL, Charkowski D, Donham KJ. Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees, and humans. Drug Metab Dispos 8:422-424 (1980).
143. Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 27:216-248 (1994).